Published in J Clin Oncol on January 05, 2009
Adult acute lymphoblastic leukemia: concepts and strategies. Cancer (2010) 1.78
Pneumonia during remission induction chemotherapy in patients with acute leukemia. Ann Am Thorac Soc (2013) 1.51
CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. Leuk Lymphoma (2013) 1.38
Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev Hematol (2010) 1.16
Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol (2012) 1.12
Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica (2009) 1.11
Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups. Haematologica (2012) 1.09
Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol (2012) 1.07
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer (2012) 1.06
Pathogenetic, Clinical, and Prognostic Features of Adult t(4;11)(q21;q23)/MLL-AF4 Positive B-Cell Acute Lymphoblastic Leukemia. Adv Hematol (2011) 1.05
Novel agents and biomarkers for acute lymphoid leukemia. J Hematol Oncol (2013) 1.02
Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica (2013) 1.01
Optimizing treatment in paediatric rheumatology--lessons from oncology. Nat Rev Rheumatol (2015) 0.99
Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia (2014) 0.98
The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest. Haematologica (2013) 0.96
Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer (2014) 0.94
Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. Hematol Oncol Clin North Am (2009) 0.93
How I treat acute lymphoblastic leukemia in older adolescents and young adults. Blood (2015) 0.92
Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase. J Adolesc Young Adult Oncol (2015) 0.89
Monoclonal antibodies in acute lymphoblastic leukemia. Blood (2015) 0.88
High hyperdiploidy among adolescents and adults with acute lymphoblastic leukaemia (ALL): cytogenetic features, clinical characteristics and outcome. Leukemia (2013) 0.88
Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study). J Hematol Oncol (2013) 0.88
Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia. Haematologica (2009) 0.88
Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer J (2014) 0.87
Outcome of Adolescents with Acute Lymphoblastic Leukemia Treated by Pediatrics versus Adults Protocols. Adv Hematol (2014) 0.86
Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies. Curr Hematol Malig Rep (2013) 0.86
High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003-2007. Haematologica (2012) 0.85
Prognostic relevance of CD20 in adult B-cell precursor acute lymphoblastic leukemia. Haematologica (2010) 0.85
Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia. Drug Des Devel Ther (2016) 0.83
Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. Haematologica (2014) 0.82
An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. Haematologica (2016) 0.80
Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trial. PLoS One (2014) 0.79
A case of me: clinical cancer sequencing and the future of precision medicine. Cold Spring Harb Mol Case Stud (2015) 0.78
Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells. Mediterr J Hematol Infect Dis (2015) 0.78
Cellular therapies in acute lymphoblastic leukemia. Hematol Oncol Clin North Am (2011) 0.78
Treatment of adolescent and young adults with acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis (2014) 0.78
Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia. Haematologica (2015) 0.77
Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival. Leukemia (2015) 0.77
Resistance revealed in acute lymphoblastic leukemia. Nat Med (2013) 0.76
Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy. Int J Gen Med (2015) 0.76
Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial. Leukemia (2016) 0.76
Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0. J Cell Mol Med (2016) 0.75
The prognostic value of glucocorticoid receptors for adult acute lymphoblastic leukemia. Blood Res (2015) 0.75
Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults. J Adolesc Young Adult Oncol (2016) 0.75
Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis. Blood (2017) 0.75
Current status and future directions of clinical research and practice in adult acute lymphoblastic leukemia patients in Korea. Blood Res (2014) 0.75
Antigen-based immunotherapy for the treatment of acute lymphoblastic leukemia: the emerging role of blinatumomab. Immunotargets Ther (2014) 0.75
Modern therapy of young and adult Ph-ALL. Leuk Suppl (2012) 0.75
Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. Am J Hematol (2016) 0.75
Recent advances and novel treatment paradigms in acute lymphocytic leukemia. Ther Adv Hematol (2016) 0.75
Hepatomegaly and fever at the time of neutrophil recovery revealing L-asparaginase toxicity in the treatment of acute lymphoblastic leukemia. Am J Case Rep (2014) 0.75
L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. J Pharmacol Pharmacother (2016) 0.75
Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia. Onco Targets Ther (2017) 0.75
Management and treatment of relapsed or refractory Ph(-) B-precursor ALL: a web-based, double-blind survey of EU clinicians. BMC Cancer (2015) 0.75
A childhood chemotherapy protocol improves overall survival among adults with T-lymphoblastic lymphoma. Oncotarget (2016) 0.75
Role of allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis (2014) 0.75
Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia. Rev Bras Hematol Hemoter (2014) 0.75
Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study. Blood Cancer J (2016) 0.75
Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study. Cancer (2016) 0.75
Bone Marrow Necrosis in Newly Diagnosed Acute Leukemia: Two Case Reports and Review of the Literature. Oncol Ther (2017) 0.75
The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance. Leuk Res (2016) 0.75
Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: efficacy and long-term safety in a single institution. Invest New Drugs (2011) 0.75
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest (2008) 9.42
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol (2009) 6.54
Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol (2010) 4.09
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet (2012) 4.03
Fate of biomedical research protocols and publication bias in France: retrospective cohort study. BMJ (2005) 3.28
Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest (2007) 3.28
BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24
Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell (2011) 3.12
HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood (2005) 3.09
DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med (2005) 3.06
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest (2010) 2.96
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood (2002) 2.71
Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res (2004) 2.52
Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med (2012) 2.51
Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med (2008) 2.49
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood (2013) 2.42
Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology (2008) 2.39
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood (2009) 2.38
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood (2013) 2.38
Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood (2007) 2.36
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol (2013) 2.22
Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood (2002) 2.21
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. J Clin Oncol (2008) 2.20
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood (2009) 2.18
Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Français de Cytogénétique Hématologique (GFCH). Blood (2002) 2.17
Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol (2006) 2.16
Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol (2003) 2.15
Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica (2008) 2.15
Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol (2004) 2.11
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer (2005) 2.08
Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood (2002) 2.06
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica (2007) 2.03
Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood (2002) 2.03
Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med (2005) 2.02
Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood (2005) 2.01
A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet (2011) 1.99
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica (2009) 1.95
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol (2010) 1.90
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood (2008) 1.87
High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. Blood (2012) 1.84
Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood (2007) 1.83
Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2009) 1.82
Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol (2008) 1.80
Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy. Crit Care Med (2005) 1.78
NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood (2005) 1.78
Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell (2006) 1.74
Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood (2005) 1.74
Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders. J Clin Microbiol (2006) 1.71
NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood (2008) 1.69
Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol (2009) 1.67
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood (2007) 1.67